Food and Drug Administration

Anesthetic & Life Support Drugs Advisory Committee

September 10, 2003



The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Palladone™ Capsules Risk Management Program, Purdue (HTM) (PPT)

Abuse Liability of Hydromorphone Extended Release Capsules, Dr. Silvia Calderon, PhD, FDA (HTM) (PPT)

Long Acting Opioids: Challenges in Pharmacotherapy, Dr. Mary Kreek, MD, The Rockefeller University (HTM) (PPT)

Risk Management of Modified-Release Opiate Analgesics: Palladone, Dr. Sharon Hertz, MD, FDA (HTM) (PPT)

Open Public Hearing

Sustained-Release Hydromorphone (Palladone)--Risks vs. Benefits Discussion, Dr. Art Zee, MD, St. Charles, VA (HTM) (PPT)